The role of RANK-ligand inhibition in cancer: the story of denosumab.

Oncologist · 2011 · PMC3228090 · PMID 21285392

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although this study showed a trend toward superiority of denosumab versus zoledronic acid in delaying the time to first on-study SRE in patients with advanced solid tumors and multiple myeloma, further trials in myeloma patients are needed to support the use of denosumab in this population.

also in 53,322 other papers

a nonsignificant trendno p-value reported

There was also a nonsignificant trend toward fewer SREs in the denosumab group versus the i.v.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.